Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label Randomized Study of Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (SPARC)

NCT03964337 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT03964337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03964337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label Randomized Study of Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (SPARC)
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Terminated
Start date
March 17, 2020
Completion date
June 4, 2021
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-metastatic, prostate cancer, prostate cancer adenocarcinoma